# US 2002/0001619 A1 · Sustained-release alginate gels

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001619 A1
- Document ID: US20020001619A1
- Status: Published application
- Kind: A1
- Application number: 08/842,756
- Filed: 1997-04-17
- Published: 2002-01-03
- Earliest claimed: 1997-04-17
- Assignees: Amgen Inc.
- Inventors: MERRILL SEYMOUR GOLDENBERG; ALICE C. BEEKMAN
- Web page: https://patentgrep.com/patent/US20020001619A1

## CPC

- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to sustained-release formulations using alginate gel beads and methods thereof.

## Claims

### Claim 1

A sustained-release composition, comprising:
a) a hydrophilic polymer;
b) a biologically active agent; and
c) at least one precipitating agent; characterized in that the biologically active agent is co-precipitated within the hydrophilic polymer.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the precipitating agent is selected from the group consisting of polyvalent metal ions or salts, acetates, citrates, chlorides, carbonates or hydroxides thereof.

### Claim 3 (depends on 2)

The composition of claim 2 wherein the metal ion is selected from the group consisting of manganese, strontium, iron, magnesium, calcium, barium, aluminium or zinc.

### Claim 4 (depends on 3)

The composition of claim 3 wherein the precipitating agent is a polyvalent ion selected from the group consisting of zinc, calcium or a combination thereof.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the hydrophilic polymer is a polyanion.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the hydrophilic polymer is a polysaccharide.

### Claim 7 (depends on 6)

The composition of claim 6 wherein the polysaccharide is an acidic polysaccharide.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the polysaccaharide is alginate.

### Claim 9 (depends on 8)

The composition of claim 8 wherein the alginate contains at least 30% guluronic acid.

### Claim 10 (depends on 8)

The composition of claim 8 wherein the alginate consist of at least 0.05% by weight.

### Claim 11 (depends on 1)

The composition of claim 1 wherein the biologically active agent comprises a protein.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the protein consist of at least 0.01 mg/ml.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the protein is selected from the group consisting of hematopoetic factors, colony stimulating factors, anti-obesity factors, growth factors, trophic factors, and antiinflammatory factors.

### Claim 14 (depends on 11)

The composition of claim 11 wherein the protein is selected from the group consisting of leptin, G-CSF, SCF, BDNF, GDNF, NT3, GM-CSF, IL-1ra, IL2, TNF-bp, MGDF, OPG, interferons, erythropoietin, KGF and analogs or derivatives thereof.

### Claim 15 (depends on 1)

The composition of claim 1 further comprising at least two precipitating agents.

### Claim 16 (depends on 15)

The composition of claim 15 wherein at least one of the precipitating agents is selected from the group consisting of water soluble polymers.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the water soluble polymer is polyethylene glycol.

### Claim 18

A method of producing a sustained-release composition, comprising the steps of:
a) dissolving a biologically active agent and a hydrophilic polymer with a solvent to form a first mixture;
b) dissolving at least one precipitating agent in a solvent to form a second mixture;
c) adding the first mixture with the second mixture; and
d) co-precipitating the biologically active agent with the hydrophilic polymer to form a co-precipitated particle.

### Claim 19 (depends on 18)

The method of claim 18 wherein the precipitating agent is selected from the group consisting of polyvalent metal ions or salts, acetates, citrates, chlorides, carbonates or hydroxides thereof.

### Claim 20 (depends on 19)

The composition of claim 19 wherein the metal ion is selected from the group consisting of manganese, strontium, iron, magnesium, calcium, barium, aluminium or zinc.

### Claim 21 (depends on 20)

The method of claim 20 wherein the precipitating agent is a polyvalent ion selected from the group consisting of zinc, calcium or a combination thereof.

### Claim 22 (depends on 21)

The method of claim 21 wherein the precipitating agent in the second mixture consists of at least 1 mM of calcium and 0.1 mM of zinc.

### Claim 23 (depends on 18)

The method of claim 18 wherein the hydrophilic polymer is a polyanion.

### Claim 24 (depends on 18)

The method of claim 18 wherein the hydrophilic polymer is a polysaccharide.

### Claim 25 (depends on 24)

The method of claim 24 wherein the polysaccharide is an acidic polysaccharide.

### Claim 26 (depends on 25)

The method of claim 25 wherein the polysaccaharide is alginate.

### Claim 27 (depends on 26)

The method of claim 26 wherein the alginate contains at least 30% guluronic acid.

### Claim 28 (depends on 27)

The method of claim 27 wherein the first mixture consists of at least 0.05% alginate by weight.

### Claim 29 (depends on 18)

The method of claim 18 wherein the biologically active agent comprises a protein.

### Claim 30 (depends on 29)

The method of claim 29 wherein the first mixture consists of at least 0.01 mg/ml protein.

### Claim 31 (depends on 29)

The method of claim 29 wherein the protein is selected from the group consisting of hematopoietic factors, colony stimulating factors, anti-obesity factors, growth factors, trophic factors, and antiinflammatory factors.

### Claim 32 (depends on 29)

The method of claim 29 wherein protein is selected from the group consisting of leptin, G-CSF, SCF, BDNF, OPG, GDNF, NT3, GM-CSF, IL-1ra, IL2, TNF-bp, MGDF, interferons, erythropoietin, KGF and analogs or derivatives thereof.

### Claim 33 (depends on 18)

The method of claim 18 further comprising at least two precipitating agents in the second mixture.

### Claim 34 (depends on 33)

The method of claim 33 wherein at least one of the precipitating agents if selected from the group consisting of water soluble polymers.

### Claim 35 (depends on 34)

The method of claim 34 wherein the water soluble polymer is polyethylene glycol.

### Claim 36 (depends on 18)

The method of claim 18 wherein adding the first mixture to second mixture occurs by spraying, electrostatic fields, droplet addition, dispersion, or mixing, to form the coprecipitated particles.

### Claim 37 (depends on 18)

The method of claim 18 further comprising the step of isolating the co-precipitated particle.

### Claim 38 (depends on 18, 36, 37)

The sustained-release product produced by the method of claims 18, 36 and 37.

### Claim 39 (depends on 1, 15)

A pharmaceutical formulation according to claims 1 or 15 in a pharmaceutically acceptable carrier, diluent or adjuvant.

### Claim 40 (depends on 1, 15)

A method of treating an indication with a sustained-release composition according to claims 1 or 15 in a pharmaceutically acceptable carrier, diluent or adjuvant.

### Claim 41 (depends on 1, 15)

A method of treatment of a disorder selected from the group consisting of excess weight, diabetes, high blood lipid level, artherial sclerosis, artherial plaque, the reduction or prevention of gall stones formation, insufficient lean tissue mass, insufficient sensitivity to insulin, and stroke, with a sustained-release composition according to claims 1 or 15 in a pharmaceutically acceptable carrier, diluent, or adjuvant wherein the biologically active agent is leptin, an analog or derivative thereof

### Claim 42 (depends on 1, 15)

A method of treating a disorder selected from the group consisting of hematopoietic cell deficiencies, infection, and neutropenia with a sustained-release composition according to claims 1 or 15 in a pharmaceutically acceptable carrier, diluent, or adjuvant wherein the biologically active agent is G-CSF, an analog or derivative thereof.

### Claim 43 (depends on 1, 15)

A method of treating inflammation with a sustained-release composition according to claims 1 or 15 in a pharmaceutically acceptable carrier, diluent, or adjuvant, wherein the biologically active agent is an IL-1ra, an analog or derivative thereof.
